Is the excitement surrounding chipmaker Nvidia fading? Whether that's due to its high valuation, concerns about the economy, ...
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...
CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results